Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease
Sathiyapalan A, Baloush Z, Ellis P. Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease. Current Oncology 2023, 30: 9514-9529. PMID: 37999109, PMCID: PMC10670056, DOI: 10.3390/curroncol30110689.Peer-Reviewed Original ResearchConceptsStage III nonsmall cell lung cancerNonsmall cell lung cancerCurative-intent therapyDisease-free survivalEvent-free survivalPathologic complete responseStandard of careOverall survivalSystemic therapyUnresectable stage III nonsmall cell lung cancerResectable nonsmall cell lung cancerImmune checkpoint inhibitor therapyAddition of durvalumabPalliative systemic therapyBest supportive careCheckpoint inhibitor therapyNeoadjuvant systemic therapyManagement of patientsCell lung cancerConsolidation durvalumabPerioperative therapyConcurrent chemoradiationMultimodality therapySupportive careSurgical resection